Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results

On April 24,2018 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) reported that it will report its first quarter 2018 financial results after market close on Tuesday, May 1, 2018 (Press release, Rigel, APR 24, 2018, View Source;p=RssLanding&cat=news&id=2344145 [SID1234525622]). Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 3691625. The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com. The webcast will be archived and available for replay for 30 days after the call via the Rigel website

Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018

On April 24, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018, after the close of the financial markets (Press release, Jazz Pharmaceuticals, APR 24, 2018, View Source;p=RssLanding&cat=news&id=2344305 [SID1234525640]). Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss first quarter 2018 financial results and provide a business and financial update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at View Source Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.

Audio webcast/conference call:
U.S. Dial-In Number: +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 9868758

A replay of the conference call will be available through May 15, 2018 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number: +1 404 537 3406
Passcode: 9868758

10-Q – Quarterly report [Sections 13 or 15(d)]

Biogen has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018

On April 24, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform reported that it will report its financial results for the first quarter ended March 31, 2018, and provide a business update on May 10, 2018 after the close of the U.S. financial markets (Press release, RXi Pharmaceuticals, APR 24, 2018, View Source [SID1234525623]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will begin at 4:30 p.m. EDT. The webcast link is available under the "Investors – Events and Presentations" section of the Company’s website, www.rxipharma.com. The event may also be accessed by dialing toll-free in the United States: +1 844-376-4678. International participants may access the event by dialing: +1 209-905-5958.

An archive of the webcast will be available on the company’s website approximately two hours after the presentation.

Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference

On April 24, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9th, at The InterContinental Boston. Mathai Mammen, MD, Ph.D., Global Head, Research & Development, Janssen Research and Development will represent the Company in a session scheduled at 9:20 a.m. (Eastern Time) (Press release, Johnson & Johnson, APR 24, 2018, View Source [SID1234525641]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately two hours after the live webcast.